Redhill Biopharma Ltd (STU:2RH0)
€ 0.431 0.029 (7.21%) Market Cap: 13.74 Mil Enterprise Value: 9.70 Mil PE Ratio: 0 PB Ratio: 4.52 GF Score: 49/100

Q2 2020 Redhill Biopharma Ltd Earnings Call Transcript

Aug 13, 2020 / 12:30PM GMT
Release Date Price: €308 (+4.05%)
Operator

Good day, ladies and gentlemen, and thank you all for standing by. Welcome to RedHill Biopharma's Second Quarter 2020 Financial Results Conference Call. (Operator Instructions) Please be advised that today's call is being recorded Thursday, the 13th of August 2020.

And without any further delay, I would like to introduce the RedHill's executive who'll be with you on this call: CEO, Mr. Dror Ben-Asher; Mr. Micha Ben-Chorin, Chief Financial Officer; Mr. Rick Scruggs, Chief Commercial Officer; Mr. Gilead Raday, Chief Operating Officer; Mr. Guy Goldberg, Chief Business Officer; and Mr. Adi Frish, Senior Vice President, Business Development and Licensing.

Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.

Unidentified Company Representative

This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to RedHill's expectations regarding the closing of the strategic agreements with Cosmo Pharmaceuticals, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot